NPCE Quote, Financials, Valuation and Earnings

Henry Schein has a net margin of -24.46% compared to NeuroPace's net margin of 2.95%. NeuroPace's return on equity of -216.38% beat Henry Schein's return on equity of 7.8%.

NeuroPace has a consensus price target of $16.86, signalling upside risk potential of 61.62%. On the other hand Henry Schein has an analysts' consensus of $77.96 which suggests that it could grow by 23.18%. Given that NeuroPace has higher upside potential than Henry Schein, analysts believe NeuroPace is more attractive than Henry Schein.

NeuroPace has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Henry Schein has a beta of 0.844, suggesting its less volatile than the S&P 500 by 15.587%.

NeuroPace has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Henry Schein offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroPace pays -- of its earnings as a dividend. Henry Schein pays out -- of its earnings as a dividend.

NeuroPace quarterly revenues are $21.5M, which are smaller than Henry Schein quarterly revenues of $3.2B. NeuroPace's net income of -$5.3M is lower than Henry Schein's net income of $94M. Notably, NeuroPace's price-to-earnings ratio is -- while Henry Schein's PE ratio is 20.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroPace is 3.80x versus 0.64x for Henry Schein. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of -24.46% compared to NeuroPace's net margin of -72.93%. NeuroPace's return on equity of -216.38% beat Standard BioTools's return on equity of -36.54%.

NeuroPace has a consensus price target of $16.86, signalling upside risk potential of 61.62%. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 110.18%. Given that Standard BioTools has higher upside potential than NeuroPace, analysts believe Standard BioTools is more attractive than NeuroPace.

NeuroPace has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.541, suggesting its more volatile than the S&P 500 by 54.101%.

NeuroPace has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroPace pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

NeuroPace quarterly revenues are $21.5M, which are smaller than Standard BioTools quarterly revenues of $46.7M. NeuroPace's net income of -$5.3M is higher than Standard BioTools's net income of -$34.1M. Notably, NeuroPace's price-to-earnings ratio is -- while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroPace is 3.80x versus 2.29x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR has a net margin of -24.46% compared to NeuroPace's net margin of -111.78%. NeuroPace's return on equity of -216.38% beat LENSAR's return on equity of -134.77%.

NeuroPace has a consensus price target of $16.86, signalling upside risk potential of 61.62%. On the other hand LENSAR has an analysts' consensus of $15.00 which suggests that it could grow by 9.09%. Given that NeuroPace has higher upside potential than LENSAR, analysts believe NeuroPace is more attractive than LENSAR.

NeuroPace has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NeuroPace has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroPace pays -- of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend.

NeuroPace quarterly revenues are $21.5M, which are larger than LENSAR quarterly revenues of $16.7M. NeuroPace's net income of -$5.3M is higher than LENSAR's net income of -$18.7M. Notably, NeuroPace's price-to-earnings ratio is -- while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroPace is 3.80x versus 2.96x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.

Patterson Companies has a net margin of -24.46% compared to NeuroPace's net margin of 1.99%. NeuroPace's return on equity of -216.38% beat Patterson Companies's return on equity of 14.22%.

NeuroPace has a consensus price target of $16.86, signalling upside risk potential of 61.62%. On the other hand Patterson Companies has an analysts' consensus of $30.42 which suggests that it could fall by -2.92%. Given that NeuroPace has higher upside potential than Patterson Companies, analysts believe NeuroPace is more attractive than Patterson Companies.

NeuroPace has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Patterson Companies has a beta of 0.731, suggesting its less volatile than the S&P 500 by 26.948%.

NeuroPace has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Patterson Companies offers a yield of 3.32% to investors and pays a quarterly dividend of $0.26 per share. NeuroPace pays -- of its earnings as a dividend. Patterson Companies pays out 52.89% of its earnings as a dividend. Patterson Companies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

NeuroPace quarterly revenues are $21.5M, which are smaller than Patterson Companies quarterly revenues of $1.6B. NeuroPace's net income of -$5.3M is lower than Patterson Companies's net income of $31.3M. Notably, NeuroPace's price-to-earnings ratio is -- while Patterson Companies's PE ratio is 20.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroPace is 3.80x versus 0.43x for Patterson Companies. Usually stocks with elevated PS ratios are considered overvalued.